AJANTA PHARMA LTD. - 532331 - Business Responsibility and Sustainability Reporting (BRSR)
Pursuant to your e-mail dated 1st September 2022, please find enclosed BRSR for the financial year 2021-22. The same is being separately submitted as advised vide the above-referred communication. This is for your information and records. AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 29, 2022 for Ravi P Agrawal, trustee Ravi Agrawal Trust AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 05, 2022 for Aayush Agrawal, trustee Aayush Agrawal Trust AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 04, 2022 or Aayush Agrawal (Trustee Aayush Agrawal Trust) AJANTA PHARMA LTD. - 532331 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Ajanta Pharma Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here AJANTA PHARMA LTD. - 532331 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Pursuant to Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following: a. Details of voting results through remote e-voting and at the AGM on each of the resolutions set out in the notice; b. Consolidated Scrutinizer's Report dated 4th August 2022 on remote e-voting and at the AGM. AJANTA PHARMA LTD. - 532331 - Proceeding Of 43Rd Annual General Meeting
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith summary of proceedings of 43rd Annual General Meeting of the Company held on 4th August 2022 through Video- conference/Other Audio-Visual Means. AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Further to our communication dated 29th July 2022 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed written transcript of the earnings call held on 28th July 2022 at 5.00 p.m. Further, written transcript has been uploaded on the Company's website and can be accessed through the link: http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ1(Apr-Jun)2022-23.pdf This is for your information and records please. AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst/Institutional Investor Meeting with the Company. AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 02, 2022 for Aayush Agrawal, trustee Aayush Agrawal Trust